2024 ESMO｜肺癌重磅药物研究Oral + Mini Oral前瞻

摘要号及标题：

1253O - I/II期ALKOVE-1研究：NVL-655治疗ALK阳性实体瘤

1253O - Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors

讲者：Alexander E. Drilon (New York, United States of America, NY)

讲座时间：09:40 - 09:50

摘要号及标题：

608O - 在晚期胰腺癌（PC）、结直肠癌（CRC）和非小细胞肺癌（NSCLC）成人患者中应用首创的 KRAS G12D 选择性蛋白降解剂 ASP3082 的初步安全性和临床活性

608O - Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)

讲者：Wungki Park (New York, United States of America)

讲座时间：14:45 - 14:55

摘要号及标题：

1786MO - BMS-986012（抗岩藻糖基单唾液酸神经节苷脂-1 [fuc-GM1]）与卡铂+依托泊苷+nivolumab一线治疗广泛期小细胞肺癌的随机II期研究的中期分析

1786MO - BMS-986012 (anti-fucosyl-monosialoganglioside-1 [fuc-GM1]) with carboplatin + etoposide + nivolumab (CE/NIVO) as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC): interim analysis (IA) of a randomized phase 2 study

讲者：Ewa Kalinka (Łódź, Poland)

讲座时间：14:05 - 14:10

摘要号及标题：

1910MO - ARTIMES研究：间皮瘤治疗疗效的自动评估

1910MO - ARTIMES: Automated Response evaluation to Treatment In MESothelioma

讲者：Kevin B. Groot Lipman (Amsterdam, Netherlands)

讲座时间：14:50 - 14:55

摘要号及标题：

1240MO - 定量放射组学用于检测Ⅲ期不可切除NSCLC患者放化疗后有症状的肺炎

1240MO - Quantitative radiomics for the detection of symptomatic pneumonitis following chemoradiotherapy in patients with Stage III unresectable NSCLC

讲者：Jarushka Naidoo (Dublin, Ireland, MD)

讲座时间：14:55 - 15:00

摘要号及标题：

1241MO - III期LAURA研究：奥希替尼治疗不可切除的EGFR突变III期NSCLC的中枢神经系统和远处进展结果分析

1241MO - Osimertinib (osi) after definitive chemoradiotherapy (CRT) in unresectable (UR) stg III EGFRm NSCLC: Analyses of CNS and distant progression from the Phase 3 LAURA study

讲者：陆舜（上海交通大学医学院附属胸科医院）

讲座时间：14:45 - 14:50

摘要号及标题：

1206MO - ALINA研究：阿来替尼 vs 化疗辅助治疗可切除的ALK+ NSCLC患者的探索性生物标志物分析

1206MO - ALINA: exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo)

讲者：Ben J. Solomon (Melbourne, Australia, VIC)

讲座时间：14:50 - 14:55

摘要号及标题：

1207MO - II期POTENTIAL研究：纳武利尤单抗单药新辅助治疗高危临床Ⅰ期NSCLC

1207MO - Neoadjuvant nivolumab monotherapy for high-risk clinical stage I non-small cell lung cancer: A phase 2 POTENTIAL study.

讲者：Yasuhiro Tsutani (Osaka, Japan, Hiroshima)

讲座时间：15:00 - 15:05

摘要号及标题：

1242MO - 在根治性放疗基础上加用丙酸倍氯米松吸入剂治疗局部晚期NSCLC患者：一项随机对照、开放标签的Ⅱ期研究

1242MO - The addition of belomethason propionate inhalation to radical radiotherapy for patients with locally advanced non-small cell lung cancer: a randomized controlled, open-label phase II study

讲者：张洁教授（上海市肺科医院）

讲座时间：15:45 - 15:50

摘要号及标题：

1208MO - Ⅲ期NEJ034研究：围手术期吡非尼酮治疗肺癌合并特发性肺纤维化 (IPF) 

1208MO - Phase III trial of perioperative pirfenidone therapy for lung cancer with idiopathic pulmonary fibrosis (IPF): NEJ034 study

讲者：Yukinobu Goto (Tsukuba, Japan)

讲座时间：15:50 - 15:55

摘要号及标题：

1243MO - Ⅲ期JCOG1914研究：比较每周卡铂+白蛋白紫杉醇 vs 每日低剂量卡铂用于不可切除局部晚期NSCLC老年患者（≥75岁）的同步化放疗

1243MO - A phase III study comparing weekly carboplatin plus nab-paclitaxel and daily low-dose carboplatin for concurrent chemoradiotherapy in elderly patients (≥75 years) with unresectable locally advanced NSCLC: JCOG1914

讲者：Shota Omori (Yufu, Japan)

讲座时间：15:55 - 16:00

摘要号及标题：

1254MO - Zipalertinib用于既往接受过Amivantamab治疗的EGFR 20外显子插入突变NSCLC患者的安全性和抗肿瘤活性

1254MO - Safety and Antitumor Activity of Zipalertinib in NSCLC Patients (pts) with EGFR Exon 20 Insertion (ex20ins) Mutations Who Received Prior Amivantamab

讲者：Antonio Passaro (Milan, Italy)

讲座时间：10:20 - 10:25

摘要号及标题：

1255MO - 一项PM8002/BNT327联合化疗用于EGFR突变NSCLC安全性和疗效性的II期研究

1255MO - A Phase II Safety and Efficacy Study of PM8002/BNT327 in Combination with Chemotherapy in Patients with EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)

讲者：吴一龙（广东省人民医院）

讲座时间：10:25 - 10:30

摘要号及标题：

1256MO - I/II期ARROS-1研究：zidesamtinib (NVL-520)用于ROS1融合突变的实体瘤患者

1256MO - Phase 1/2 ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumors

讲者：Benjamin Besse (Villejuif, Cedex, France, CEDEX)

讲座时间：10:30 - 10:35

摘要号及标题：

1257MO - c-Met 蛋白靶向抗体-药物共轭物 (ADC)—— ABBV-400 用于晚期EGFR野生型非鳞状NSCLC患者的I期研究结果

1257MO - ABBV-400, a c-Met Protein–Targeting Antibody-Drug Conjugate (ADC), in Patients (Pts) With Advanced EGFR Wildtype (WT) Non-Squamous (NSQ) Non-Small Cell Lung Cancer (NSCLC): Results From a Phase 1 Study

讲者：María De Miguel (Madrid, Spain)

讲座时间：11:00 - 11:05

摘要号及标题：

1258MO - NVALT-30临床试验计划前的中期分析：低剂量 vs 标准剂量帕博利珠单抗治疗IV期NSCLC的

1258MO - Low dose versus standard dose pembrolizumab for treatment of stage 4 stage non-small cell lung carcinoma: Results of the pre-planned interim analysis of the NVALT-30 clinical trial.

讲者：Michel Van den Heuvel (Nijmegen, Netherlands)

讲座时间：11:05 - 11:15

摘要号及标题：

1259MO - IFCT-1904 ENCO-BRAF研究：一项Encorafenib + binimetinib用于初治 BRAF V600E 突变晚期NSCLC 的一项开放标签、多中心、II期试验

1259MO - Encorafenib plus binimetinib in patients (pts) with previously untreated BRAF V600E-mutant advanced Non-Small Cell Lung Cancer (NSCLC): an open-label, multicenter phase 2 trial (IFCT-1904 ENCO-BRAF)

讲者：David Planchard (Villejuif, Cedex, France)

讲座时间：11:40 - 11:45